Results 201 to 210 of about 5,640,382 (269)

Low‐intensity focused ultrasound neuromodulation for drug‐resistant epilepsy: A randomized, sham‐controlled crossover trial

open access: yesEpilepsia, EarlyView.
Abstract Objective This study was undertaken to evaluate the safety, feasibility, and efficacy of low‐intensity focused ultrasound (LIFU) as a noninvasive neuromodulation technique in patients with drug‐resistant epilepsy (DRE). Methods In this pilot, single‐blind, randomized sham‐controlled crossover trial, 12 patients with DRE underwent both LIFU and
Chien‐Chen Chou   +8 more
wiley   +1 more source

Monthly or menstrual? A scoping review of catamenial epilepsy and non‐menstrual seizure rhythms

open access: yesEpilepsia, EarlyView.
Abstract Objective Despite the reported high prevalence of catamenial epilepsy (CE), the condition remains poorly defined, with lack of consensus on what entails a menstrual‐related seizure exacerbation. Emerging evidence of multiday cycles of seizure activity, including about‐monthly cycles, present in both men and women, further confound the ...
Victoria Wong   +4 more
wiley   +1 more source

Enhancing quality of mental health service for veterans with seizures

open access: yesEpilepsia, EarlyView.
Abstract Psychiatric disorders are commonly identified in people with seizures (PWS). Comorbid mood, anxiety, and trauma‐ and stressor‐related disorders are highly prevalent and not consistently recognized or treated promptly. Veterans with seizures are particularly vulnerable to neuropsychiatric comorbidities, including a higher prevalence of ...
Maria Raquel Lopez   +6 more
wiley   +1 more source

Beyond seizure control: Non–seizure‐related outcomes in focal‐onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study

open access: yesEpilepsia, EarlyView.
Abstract Objective Cenobamate is approved for treatment of focal seizures in adults, but evidence on non‐seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal‐onsEt SeizureS (BLESS) study evaluated patient‐ and clinician‐reported outcomes for up to 52 weeks of cenobamate treatment.
Simona Lattanzi   +206 more
wiley   +1 more source

DECREASE study: A European pool‐analysis of patients with significant reductions in concomitant antiseizure medications in cenobamate Early Access Programs

open access: yesEpilepsia Open, EarlyView.
Abstract Objective To evaluate the effectiveness and tolerability of cenobamate in patients with a significant reduction in concomitant antiseizure medication (ASM) in European cenobamate Early Access Programs (EAPs). Method Anonymized patient data from real‐world studies/registries associated with European cenobamate EAPs were pooled.
Vicente Villanueva   +25 more
wiley   +1 more source

Age-specific and gender-dependent impact of primary headache disorders on dementia risk: Population-based longitudinal study. [PDF]

open access: yesMedicine (Baltimore), 2018
Yin JH   +11 more
europepmc   +1 more source

Aphasic status epilepticus due to Epstein–Barr virus meningoencephalitis – A clinical vignette

open access: yes
Epileptic Disorders, EarlyView.
Gemma Bassani   +6 more
wiley   +1 more source

Eating Disorder Clinician Views About the Impact of Out‐of‐Home Calorie Labelling on Their Patients: A Qualitative Interview Study

open access: yesEuropean Eating Disorders Review, EarlyView.
ABSTRACT Objective Accumulating evidence suggests that people with eating disorders experience mainly negative impacts of out‐of‐home calorie labelling. This study explored eating disorder clinician perspectives on how such labels affect individuals with eating disorders, and their views on implementation of this policy.
Abinaya Nadarajah   +9 more
wiley   +1 more source

Increased risk of sleep apnoea among primary headache disorders: a nationwide population-based longitudinal study. [PDF]

open access: yesPostgrad Med J, 2019
Yin JH   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy